

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

PE/CA-PJ41 (clone D2)

RRID:CVCL_2680

Type: Cell Line

Proper Citation

RRID:CVCL_2680

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2680

Proper Citation: RRID:CVCL_2680

Description: Cell line PE/CA-PJ41 (clone D2) is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Oral cavity squamous cell carcinoma

Defining Citation: [PMID:9876219](#), [PMID:22460905](#), [PMID:30894373](#), [PMID:31068700](#)

Comments: Population: Caucasian., Part of: KuDOS 95 cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: PE/CA-PJ41 (clone D2)

Synonyms: PECAPJ41CLONED2, PE-CA-PJ41-cl D2, PE/CA-PJ-41, PE CA PJ41, PECAPJ41, Plaepi 41

Cross References: CLO:CLO_0008409, ArrayExpress:E-MTAB-2770, BioSample:SAMN10988012, cancercellines:CVCL_2680, Cell_Model_Passport:SIDM01323, Cosmic:1339922, DepMap:ACH-000732, ECACC:98020207, GEO:GSM887510, GEO:GSM888592, GEO:GSM1374830, GEO:GSM1374831, IARC_TP53:28261, LiGeA:CCLE_664, PharmacDB:PE_CAPJ41_cloneD2_1258_2019, Progenetix:CVCL_2680, Wikidata:Q54946884

ID: CVCL_2680

Record Creation Time: 20220427T221427+0000

Record Last Update: 20260829T235616+0000

Ratings and Alerts

No rating or validation information has been found for PE/CA-PJ41 (clone D2).

No alerts have been found for PE/CA-PJ41 (clone D2).

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Xu C, et al. (2026) HOMER3 drives oral squamous cell carcinoma progression through TRPV6 calcium influx and TUBB3 microtubule stabilization. *Oncogene*, 45(2), 278.

Zhu T, et al. (2025) Endogenous YAP/TAZ partitioning in TEAD condensates orchestrates the Hippo response. *Molecular cell*.

Chan HHY, et al. (2025) RAC1-Amplified and RAC1-A159V Hotspot-Mutated Head and Neck Cancer Sensitive to the Rac Inhibitor EHop-016 In Vivo: A Proof-of-Concept Study. *Cancers*, 17(3).

Gu Z, et al. (2022) Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma. *BMC medicine*, 20(1), 175.